SAKAR Stock Overview
Research, develops, manufactures, and markets pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sakar Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹303.55 |
| 52 Week High | ₹479.00 |
| 52 Week Low | ₹279.85 |
| Beta | 0.31 |
| 1 Month Change | 6.56% |
| 3 Month Change | -6.66% |
| 1 Year Change | -17.78% |
| 3 Year Change | 117.52% |
| 5 Year Change | 356.12% |
| Change since IPO | 494.03% |
Recent News & Updates
Recent updates
Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think
Oct 30
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Dec 28Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Aug 05Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Mar 29Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors
Jan 31Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?
Dec 01Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Jul 13Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Mar 26With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting
Jul 01Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today
Mar 23Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares
Mar 02Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Feb 08Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Jan 10Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock
Dec 14Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?
Nov 22
Shareholder Returns
| SAKAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.9% | 0.8% | -4.2% |
| 1Y | -17.8% | 39.7% | 19.1% |
Return vs Industry: SAKAR underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: SAKAR underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| SAKAR volatility | |
|---|---|
| SAKAR Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SAKAR has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SAKAR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 325 | Sanjay Shah | www.sakarhealthcare.com |
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins.
Sakar Healthcare Limited Fundamentals Summary
| SAKAR fundamental statistics | |
|---|---|
| Market cap | ₹6.60b |
| Earnings (TTM) | ₹124.03m |
| Revenue (TTM) | ₹1.65b |
53.2x
P/E Ratio4.0x
P/S RatioIs SAKAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAKAR income statement (TTM) | |
|---|---|
| Revenue | ₹1.65b |
| Cost of Revenue | ₹911.33m |
| Gross Profit | ₹738.93m |
| Other Expenses | ₹614.90m |
| Earnings | ₹124.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.70 |
| Gross Margin | 44.78% |
| Net Profit Margin | 7.52% |
| Debt/Equity Ratio | 31.1% |
How did SAKAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sakar Healthcare Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|